Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib and Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC
NCT06018688Phase 2Not yet recruiting
- Start
- Sep 2023
- Primary completion
- Mar 2026
- Modality
- Orthosteric Ligands
01
Overview
A Phase 2 trial of osimertinib, aspirin in non-small cell lung cancer (NSCLC). Planned start Sep 2023; status: not yet recruiting.
02
Drugs
osimertinibaspirin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06018688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06018688.